Loading clinical trials...
Loading clinical trials...
Primary Objectives: 1. (Phase I) To establish the maximum tolerated dose and dose-limiting toxicities of the combination of OSI-774 (Tarceva™) and rhuMAb VEGF (Avastin™) in patients with advanced Non...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
M.D. Anderson Cancer Center
Collaborators
NCT06689488 · Lung Cancer
NCT07668037 · Non-Small Cell Carcinoma of Lung, Immunotherapy, and more
NCT06500481 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, and more
NCT00899405 · Lung Cancer
NCT02682667 · Multiple Myeloma, Lymphoma, Non-Hodgkin, and more
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
University of Texas M.D. Anderson Cancer Center
Houston, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions